Remove 2023 Remove Assay Development Remove Pharmacokinetics
article thumbnail

Choosing the Best Bioanalytical Platform for Your Program

Alta Sciences

Choosing the Best Bioanalytical Platform for Your Program aasimakopoulos Mon, 08/21/2023 - 20:50 Choosing the right bioanalytical platform for your molecule’s intended use and program segment is crucial to obtaining reliable, robust data in a timely manner. Why Partner With Altasciences for Your Bioanalytical Projects?

article thumbnail

The essential role of recombinant phage display antibody libraries

Drug Target Review

Overcoming traditional antibody generation limitations with recombinant technologies Antibodies remain essential tools in this ever-changing field for preclinical bioanalysis and drug monitoring through ligand-binding assays (LBAs). Adapted from Harth S et al. (8) 8) under a CC BY-NC-ND 4.0. Crescioli S, Kaplon H, Chenoweth A, et al.

article thumbnail

Article EMA Thank You EMA finalizes clinical anticancer therapeutic guidance update

Agency IQ

The protocol and statistical analysis plan should clearly specify the plans for specimen collection, sample analysis and related clinical outcomes depending on the biomarker assay development and validation strategy. Second, the EMA is working on a separate guideline for platform trials , floating a concept paper in 2022.